Propanc Biopharma, Inc.
$0.12
▲
4.74%
2026-04-21 08:55:01
www.propanc.com
NCM: PPCB
Explore Propanc Biopharma, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$2.33 M
Current Price
$0.12
52W High / Low
$11 / $0.1
Stock P/E
—
Book Value
$0.78
Dividend Yield
—
ROCE
-407.57%
ROE
-18.12%
Face Value
—
EPS
$52.11
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
1
Beta
3.52
Debt / Equity
5.67
Current Ratio
2.13
Quick Ratio
1.5
Forward P/E
—
Price / Sales
—
Enterprise Value
$2.64 M
EV / EBITDA
-0.04
EV / Revenue
—
Rating
None
Target Price
—
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | InflaRx N.V. | $1.66 | — | $120.01 M | — | -114.26% | -88.63% | $1.94 / $0.71 | $0.67 |
| 2. | ACADIA Pharmaceuticals Inc. | $22.09 | 9.63 | $3.77 B | — | 8.14% | 39.89% | $28.35 / $14.08 | $7.21 |
| 3. | Protagonist Therapeutics, Inc. | $104.42 | — | $6.74 B | — | -25.39% | -20.18% | $107.84 / $41.28 | $9.82 |
| 4. | Ocugen, Inc. | $1.85 | — | $606.61 M | — | -307.31% | -7.77% | $2.73 / $0.64 | $-0.04 |
| 5. | Immunic, Inc. | $0.95 | — | $124.59 M | — | 1572.16% | -16.53% | $1.51 / $0.51 | $-0.06 |
| 6. | IGC Pharma, Inc. | $0.32 | — | $31.52 M | — | -114.73% | -83.34% | $0.5 / $0.24 | $0.09 |
| 7. | IDEAYA Biosciences, Inc. | $33.6 | — | $2.95 B | — | -15.17% | -10.92% | $39.28 / $16.07 | $11.65 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -3.65 M | -4.67 M | -3.65 M | -53.13 M | -0.21 M | — |
| Net Profit | -3.09 M | -4.84 M | -4.07 M | -54.07 M | -0.43 M | — |
| EPS in Rs | -0.15 | -0.23 | -0.19 | -2.59 | -0.02 | -287.76 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -57.28 M | -1.54 M | -1.78 M | -1.99 M |
| Net Profit | -58.92 M | -1.82 M | -2.66 M | -2.66 M |
| EPS in Rs | -2.82 | -0.09 | -0.13 | -0.13 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 19.63 M | 0.07 M | 0.06 M | 0.08 M |
| Total Liabilities | 5.73 M | 3.85 M | 3.18 M | 3.11 M |
| Equity | 13.91 M | -3.78 M | -3.12 M | -3.02 M |
| Current Assets | 8.35 M | 0.03 M | 0.02 M | 0.02 M |
| Current Liabilities | 5.58 M | 3.79 M | 3.16 M | 3.06 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -0.41 M | -0.94 M | -1.11 M | -1.44 M |
| Investing CF | — | — | — | — |
| Financing CF | 0.49 M | 0.94 M | 1.11 M | 1.49 M |
| Free CF | -0.41 M | -0.94 M | -1.11 M | -1.44 M |
| Capex | — | — | — | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -3136.6% | 31.57% | -0.09% | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2025-01-29 | 1:0.5 |